TY - JOUR T1 - Biomarkers in COPD exacerbation, the role of adiponectin JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P3615 AU - Vlasios Vitsas AU - Matina Kardara AU - Antonia Koutsoukou AU - Pinelopi Michalopoulou AU - Stylianos Orfanos AU - Georgios Tsoukalas AU - Anastasia Kotanidou Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P3615.abstract N2 - Introduction: COPD is a condition of global importance, characterised by accelerated lung function decline and an abnormal inflammatory response. Exacerbations account for much of the morbidity and the mortality in COPD. Adiponectin is a protein that is synthesised and secreted primarily by white adipose tissue.Objectives: To record and analyse parameters such as bomarkers (adiponectin, IL6, IL8 and others), lung functions and dyspnea level on the 1st day of a COPD exacerbation, at discharge and 6 weeks after. These are preliminary results of the study.Methods: 20 patints (mean age 67,5 years) which were hospitalised for exacerbation of COPD are included so far in the study. Biomarkers such as adiponectin, leucocytes, IL6, IL8 and CRP were measured at admission, at discharge and 6 weeks after discharge. Lung function and dyspnea level were studied and measured at discharge and 6 weeks later. Results: A trend for decline was observed (p=o,10) for adiponectin levels at discharge and 6 weeks after. The adiponectin levels in patients serum with acute exacerbation of COPD before discharge from the hospital (mean 6,47μg/ml ±2,94) were higher than those measured from the same patients 6 weeks after discharge (stable COPD) (mean 6,13 ±3,71). Statistical significant differences were observed at the levels of CRP at admission and discharge (p<o,oo1) and at the levels of FEV1 % at discharge and 6 weeks after(p=0,003) as expected.Conclusion: Even though the study is still at an early stage, there are useful conclusions to be made. Adiponectin presents a decreasing trend 6 weeks after the exacerbation which indicates that it may be a valuable biomarker for the assessment of COPD severity along with FEV1and CRP. ER -